Seratrodast
Seratrodast is a thromboxane A2 receptor antagonist used for the treatment of asthma in Japan and some Asian countries, where it reduces bronchoconstriction and airway inflammation mediated by thromboxane A2. By blocking thromboxane A2 prostanoid (TP) receptors on airway smooth muscle and inflammatory cells, it inhibits bronchoconstriction, platelet aggregation, and inflammatory cell recruitment. It provides anti-asthmatic effects without the direct bronchodilatory action of beta-agonists.
Peso molecular
354,4000 g/mol
LogP
4,40
TPSA
71,40 Ų
Regla de cinco de Lipinski
Cumple
Mecanismo de acción
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Estructura 2D
Cite this structure
Embed this structure
SMILES
CC1=C(C)C(=O)C(C(CCCCCC(=O)O)c2ccccc2)=C(C)C1=O
InChI
InChI=1S/C22H26O4/c1-14-15(2)22(26)20(16(3)21(14)25)18(17-10-6-4-7-11-17)12-8-5-9-13-19(23)24/h4,6-7,10-11,18H,5,8-9,12-13H2,1-3H3,(H,23,24)
Molecular Formula
C22H26O4
HBD / HBA
1 / 4
Enlaces Rotables
8
Átomos Pesados
26
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
Seratrodast is a thromboxane A2 receptor antagonist used for the treatment of asthma in Japan and some Asian countries, where it reduces bronchoconstriction and airway inflammation mediated by thromboxane A2. By blocking thromboxane A2 prostanoid (TP) receptors on airway smooth muscle and inflammatory cells, it inhibits bronchoconstriction, platelet aggregation, and inflammatory cell recruitment. It provides anti-asthmatic effects without the direct bronchodilatory action of beta-agonists.
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Yes, Seratrodast is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL70972. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 2449. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="seratrodast"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/seratrodast/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/seratrodast/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/seratrodast/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="seratrodast"></drugfyi-drug>